Mausumee Guha

Mausumee Guha

Auto-generated profile, based on publicly available information

Mausumee Guha

Pfizer Inc., La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2019 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
CJChanghua Ji
Changhua Ji
MGMausumee Guha
Mausumee Guha
XZXu Zhu
Xu Zhu
JWJessica Whritenour
Jessica Whritenour
MHMichelle D. Hemkens
Michelle D. Hemkens
ROR. Scott Obach
R. Scott Obach

21 August 2022 in International Journal of Toxicology
Verified
Journal Article
Closed access
MGMausumee Guha
Mausumee Guha
ZSZhanna Sobol
Zhanna Sobol
MMMathew Martin
Mathew Martin
MHMichelle Hemkens
Michelle Hemkens
TSTae Sung
Tae Sung
WHWenyue Hu
Wenyue Hu
Poly(ADP-ribose) polymerase inhibitors (PARPi) are approved as monotherapies in BRCA1/2-mutated (m BRCA1/2) metastatic breast and ovarian cancers, and in advanced pancreatic and metastatic castration-resistant prostate cancers. Differential safety profiles across PARPi necessitate improved mechanistic understanding of inhibitor differences, especially with expansion of PARPi indications and drug combinations. Here, we report in vitro evaluations of PARPi (–/+ PARP trapper temozolomide, TMZ) with reference to total clinical mean concentration average or maximum (tCavg, tCmax), to elucidate contributions of primary pharmacology and structural differences to clinical efficacy and safety. In biochemical assays, rucaparib and niraparib demonstrated off-target secondary pharmacology activities, and in selectivity assays, talazoparib, olaparib, and rucaparib inhibited a broader panel of PARP enzymes. In donor-derived human bone marrow mononuclear cells, only olaparib both increased early apoptosis and decreased the cell viability half inhibitory concentration (IC50) at ≤ tCavg, whereas other PARPi only did so in the presence of TMZ. In cancer cell lines with DNA damage repair mutations, all PARPi decreased cell viability in H1048 but not TK6 cells, and only talazoparib decreased cell growth in DU145 cells at ≤ tCavg concentrations. When combined with low dose TMZ, only talazoparib left-shifted the functional consequences of PARP trapping (S-phase arrest, apoptosis, S-phase double-stranded breaks) and reduced cell viability/growth in TK6 and DU145 cell lines at ≤ tCavg, whereas the other inhibitors required high-dose TMZ. Our study suggests structural differences across PARPi may contribute to differences in PARP selectivity and off-target activities, which along with distinct pharmacokinetic properties, may influence inhibitor-specific toxicities in patients.